Bryan Johnson Longevity: The Private-Clinic Pathway They Likely Used

Who Is Bryan Johnson and Why Does His Protocol Matter Clinically?

Bryan Johnson is a 46-year-old tech entrepreneur who sold Braintree to PayPal for $800 million in 2013 and subsequently committed roughly $2 million per year to a physician-led experiment aimed at slowing and reversing biological aging. His "Blueprint" protocol is fully public, which is unusual. Most celebrity health regimens stay behind NDAs. Because Johnson publishes his labs, his exact doses, and his testing schedule, clinicians can cross-reference his approach against the peer-reviewed literature and identify which elements are evidence-backed, which remain experimental, and which a private-practice physician could replicate today for a motivated patient.

The clinical relevance is not celebrity gossip. Johnson's protocol is essentially a structured N-of-1 trial with continuous monitoring. He publishes outcomes data, including repeated epigenetic clock measurements. A 2023 analysis using the DunedinPACE epigenetic clock placed his pace of aging in the bottom 1 percent of a reference cohort of 18-year-olds, a claim that carries more weight when the underlying assay has been validated in peer-reviewed literature. [1]

Why Private Clinics Are Central to This Approach

No primary-care physician running a 15-minute appointment can replicate Blueprint. The protocol demands quarterly or more frequent lab draws, physician interpretation of continuous glucose monitor (CGM) data, and off-label prescribing of drugs that are FDA-approved for other indications. Private longevity clinics and concierge internal-medicine practices are the access point for most patients who want a scaled-down version of this model.

What "Biological Age" Actually Measures

Biological age differs from chronological age by quantifying the cumulative molecular damage in your tissues. Johnson uses multiple assays simultaneously, including Horvath's DNAm clock, the GrimAge clock, and the DunedinPACE clock, each of which predicts all-cause mortality risk independently of calendar age. [1] The American Federation for Aging Research notes that no single clock is definitive, which is why Johnson's team runs several in parallel.

The Prescription Drug Stack: What Is Confirmed and What the Evidence Shows

Johnson has publicly confirmed several prescription medications. Each sits at a different point on the evidence spectrum, from randomized-trial data to early-phase observational signals.

Rapamycin (Sirolimus)

Rapamycin is the most discussed drug in Johnson's stack. It is FDA-approved as an immunosuppressant for organ transplant recipients and as everolimus for certain cancers. [2] Its longevity interest comes from mTOR inhibition. In the Interventions Testing Program (ITP), rapamycin extended median lifespan in genetically heterogeneous mice by 9 to 14 percent even when started late in life. [3]

Johnson takes rapamycin weekly rather than daily, a dosing schedule that some longevity physicians hypothesize may reduce immunosuppressive adverse effects while preserving autophagy induction. That hypothesis has not been confirmed in a human randomized controlled trial. The PEARL trial (NCT04488601), a Phase 2 RCT of intermittent low-dose rapamycin in older adults, is ongoing as of 2025 and will provide the first controlled human data. [4]

Private-clinic pathway: A physician can prescribe sirolimus off-label after reviewing a patient's baseline immune function, lipid panel (rapamycin raises triglycerides in some patients), and renal function. Starting dose in longevity practice commonly ranges from 2 mg to 6 mg once weekly, but no standard of care exists.

Acarbose

Acarbose is an alpha-glucosidase inhibitor FDA-approved for type 2 diabetes. [2] Johnson takes it with meals to blunt post-prandial glucose spikes. In the ITP, acarbose extended median lifespan in male mice by 22 percent. [3] In humans, the STOP-NIDDM trial (N=1,429) showed that acarbose reduced progression from impaired glucose tolerance to type 2 diabetes by 25 percent over 3.3 years. [5]

For a non-diabetic patient with a fasting glucose below 100 mg/dL, acarbose is prescribed off-label. The most common adverse effects are flatulence and loose stools, which typically improve after 4 to 8 weeks of use.

Metformin

Johnson has reported using metformin intermittently. Metformin activates AMPK, mimics some caloric restriction signals, and has epidemiological associations with reduced all-cause mortality in observational data. The TAME trial (Targeting Aging with Metformin, NCT03781673) is the first FDA-approved trial designed to test a drug specifically against the process of aging rather than any single disease, and it is currently enrolling. [6] TAME uses 1,500 mg extended-release metformin daily as the intervention dose.

One concern raised by a 2023 study in Nature Aging (N=9,693) is that metformin may blunt exercise-induced adaptations in older adults. [7] Johnson's team reportedly cycles metformin around exercise blocks for this reason. Private clinicians prescribing metformin for longevity should discuss this trade-off explicitly with physically active patients.

Testosterone and Hormone Optimization

Johnson uses topical testosterone, and his testosterone levels have been publicly disclosed as mid-normal for a young adult male. Low testosterone in men over 40 is independently associated with increased cardiovascular mortality risk in large epidemiological studies. [8] The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with consistently low total testosterone (below 300 ng/dL) and symptoms of hypogonadism. [8]

A private-clinic physician evaluating a patient for testosterone optimization will obtain at minimum two morning total-testosterone measurements, LH, FSH, SHBG, estradiol, PSA, and hematocrit before initiating therapy.

The Diet and Metabolic Architecture

Johnson's dietary approach is as tightly specified as his drug stack. He eats roughly 1,977 calories per day, all before 11 a.m., in a compressed eating window that functions as time-restricted eating (TRE). He consumes no animal products and centers his intake around vegetables, nuts, seeds, and a proprietary "Blueprint" food line.

Time-Restricted Eating and Metabolic Outcomes

A 2022 NEJM study (TREAT trial, N=116) found that TRE did not produce significantly greater weight loss than unrestricted eating at the same caloric intake over 12 months. [9] However, TRE may confer benefits independent of weight, including improved insulin sensitivity and reductions in blood pressure observed in smaller mechanistic trials. Johnson's motivation for TRE appears to be post-prandial glucose control as tracked by CGM, not weight management.

Continuous Glucose Monitoring in Non-Diabetics

Johnson wears a CGM continuously. The FDA has cleared CGMs for use without a prescription (Dexcom Stelo, Abbott Lingo) as of 2024, removing the primary access barrier for non-diabetic patients. [2] A private-clinic framework for CGM use in longevity medicine typically targets a mean glucose below 100 mg/dL and time-in-range (70 to 140 mg/dL) above 95 percent. Johnson's publicly disclosed CGM data consistently shows post-prandial peaks below 110 mg/dL.

Body Composition Targets

Johnson uses DEXA scanning quarterly to track visceral adipose tissue (VAT). Excess VAT is an independent predictor of cardiovascular risk even in individuals with normal BMI. [10] A 2020 study in the Journal of the American College of Cardiology (N=12,785) found that individuals with high VAT had a 2-fold increased risk of cardiovascular events regardless of BMI category. [10] Private longevity clinics with DEXA access can provide annual VAT quantification; quarterly scanning is rarely necessary outside a research context.

Exercise: The Most Evidence-Dense Pillar

No prescription drug in Johnson's stack has a stronger evidence base for longevity than structured exercise. Johnson performs approximately one hour of daily exercise including resistance training and cardiovascular work, targeting a VO2 max above the 75th percentile for his age.

VO2 max is the single strongest predictor of all-cause mortality in large prospective cohorts. A 2018 JAMA Network Open study (N=122,007) found that individuals with elite cardiorespiratory fitness had a 5-fold lower mortality hazard than those with low fitness, an effect size larger than smoking cessation. [11] Johnson's publicly reported VO2 max is approximately 53.7 mL/kg/min, which places him near the 99th percentile for men aged 40 to 49.

Resistance Training and Muscle Mass

Muscle mass predicts longevity independently of fat mass. A 2022 study in the British Journal of Sports Medicine (N=4,449) found that resistance training two days per week was associated with a 23 percent lower risk of all-cause mortality. [12] Johnson performs daily resistance training targeting each major muscle group across the week.

Sleep Architecture as a Recovery Variable

Johnson tracks sleep with polysomnography-grade devices and targets eight hours of sleep with documented slow-wave and REM percentages. The CDC notes that adults getting fewer than 7 hours of sleep per night are at higher risk of obesity, diabetes, hypertension, and stroke. [13] Johnson's team intervenes pharmacologically on sleep architecture when tracking data shows deficits, using melatonin (300 mcg, a dose far below the typical OTC product) timed precisely to his circadian rhythm.

Supplements: Separating the Evidence-Backed From the Experimental

Johnson's published supplement list runs to more than 50 items. A clinical review of the stack reveals three tiers of evidence.

Tier 1: Strong Mechanistic and Clinical Data

Omega-3 fatty acids: The REDUCE-IT trial (N=8,179) showed icosapentaenoic acid (EPA) 4 g/day reduced major cardiovascular events by 25 percent in patients with elevated triglycerides on statins. [14] Johnson takes 3.6 g combined EPA and DHA daily.

Vitamin D3: A 2022 meta-analysis in BMJ (N=83,291 across 50 RCTs) found vitamin D supplementation reduced cancer mortality by 12 percent. [15] Johnson's protocol targets a serum 25-OH-D of 60 to 80 ng/mL.

Lithium (low dose): Epidemiological data from drinking-water studies associates higher lithium levels with lower suicide and dementia rates. A 2020 BMJ meta-analysis found an inverse relationship between drinking-water lithium and dementia incidence. [16] Johnson takes 1 mg lithium orotate daily, well below psychiatric dosing.

Tier 2: Promising but Preliminary

NMN (Nicotinamide Mononucleotide): NMN is a precursor to NAD+. Rodent studies show dramatic benefits. A 2022 double-blind RCT in humans (N=66) showed NMN 250 mg/day for 12 weeks increased muscle NAD+ levels and improved muscle insulin sensitivity in older men. [17] Human longevity outcomes remain unknown.

Spermidine: A 2021 study in Nature Aging (N=100) found dietary spermidine supplementation improved memory performance in older adults with subjective cognitive decline over 3 months. [18] Johnson takes spermidine derived from wheat germ extract.

Tier 3: Mechanistic Rationale Only

Several items in Johnson's stack (including various plant polyphenols and exotic peptides) have mechanistic rationale from in vitro or animal data but no human RCT evidence. A private-clinic physician should flag these clearly to patients and document the discussion.

The Testing and Biomarker Cadence: What a Private Clinic Can Offer

The table below maps Johnson's documented testing frequency to what a well-resourced private longevity clinic can realistically offer in 2025.

| Test | Johnson's Reported Frequency | Realistic Private Clinic Frequency | |---|---|---| | Comprehensive metabolic panel, CBC, lipids | Monthly | Quarterly | | HbA1c | Monthly | Every 3 months | | Epigenetic age (DNAm clock) | 2x per year | 1x per year | | DEXA (VAT + bone density) | Quarterly | Annual | | VO2 max exercise test | Quarterly | Annual or biannual | | CGM | Continuous | 2-week sessions quarterly | | Full-body MRI | Annual | Annual (with concierge radiology) | | Testosterone panel | Monthly | Every 3 to 6 months | | ApoB | Monthly | Quarterly |

The frequency difference matters less than the consistency of follow-up. A patient who does annual labs and actually adjusts their protocol based on results will outperform a patient who orders monthly labs and ignores them.

Cardiovascular Risk: The Biomarker Johnson Prioritizes Most

Johnson targets an LDL-C below 50 mg/dL and an ApoB below 60 mg/dL. These are more aggressive than current American Heart Association guidelines, which recommend LDL-C below 70 mg/dL only for very-high-risk cardiovascular patients. [19]

His rationale, shared by some preventive cardiologists, is that LDL-C and ApoB are causal in atherosclerosis and that the safest achievable level is optimal, not merely guideline-compliant. A 2022 Lancet meta-analysis of 34 statin trials (N=186,854) confirmed a linear relationship between LDL-C reduction and cardiovascular event reduction across the full LDL range, with no lower threshold of benefit identified. [20]

Johnson achieves his LDL target with rosuvastatin 10 mg daily and ezetimibe 10 mg daily. The combination of a statin plus ezetimibe is supported by the SHARP trial (N=9,270) and the IMPROVE-IT trial (N=18,144), both showing additive cardiovascular benefit. [20]

What a Private-Clinic Longevity Appointment Actually Looks Like

A patient presenting to a private longevity clinic for a Blueprint-inspired workup will typically go through four phases.

Phase 1: Baseline phenotyping (visit 1 to 2). This includes a comprehensive history, fasting labs (CBC, CMP, lipid panel with ApoB, LDL, HDL, fasting insulin, HbA1c, full thyroid panel, testosterone and sex hormones, inflammatory markers including hsCRP and IL-6, vitamin D, homocysteine), a resting ECG, and body composition by DEXA or bioelectrical impedance.

Phase 2: Advanced diagnostics (weeks 2 to 4). Depending on results and patient age, the physician may order a coronary artery calcium (CAC) score, a VO2 max test, a CGM trial (14 days minimum), and epigenetic age testing (TruAge, Elysium, or similar commercial labs).

Phase 3: Protocol design. The physician constructs a personalized plan addressing diet, exercise, sleep, and any appropriate off-label prescriptions with documented informed consent covering the experimental nature of longevity pharmacology.

Phase 4: Monitoring cadence. Labs at 8 to 12 weeks post-initiation to check for adverse effects (lipid changes with rapamycin, GI tolerance with acarbose or metformin), then quarterly thereafter with annual advanced imaging.